Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 7 | Arthritis Research & Therapy

Fig. 7

From: Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Fig. 7

Assessment of structural damage in week-24 certolizumab pegol (CZP) and placebo (PBO) completers. a Mean modified total Sharp score (mTSS) (Observed). b Mean change from baseline in mTSS. c Percentage of patients with no radiographic progression. No radiographic progression was defined as an mTSS change from the randomized controlled trial baseline ≤0.5

Back to article page